U.S. Entertainment Stock News

Wondering if A. O. Smith at around $68 a share is quietly undervalued or just fairly priced? You are not alone, and that is exactly what we are going to unpack here. Despite only a 1.0% return over the last year, the stock has climbed 6.9% in the past month after a softer 1.0% dip over the last week, hinting that sentiment may be shifting again. Recent headlines have focused on A. O. Smith expanding its water treatment and high efficiency water heating offerings, plus ongoing investment in...

Bank Midwest Partnership Puts Raymond James in Focus Raymond James Financial (RJF) just deepened its regional footprint through a new partnership with Bank Midwest, which is moving about $692 million in client assets and rebranding its wealth arm on Raymond James infrastructure. See our latest analysis for Raymond James Financial. That backdrop helps explain why investors have been comfortable paying around $163.01 today, with a modestly positive year to date share price return alongside a...

USA Rare Earth (USAR) has quietly turned heads after a choppy stretch, with the stock bouncing 2% in the latest session even as it remains down over the past 3 months. See our latest analysis for USA Rare Earth. With the share price now at $13.84, the stock’s 1 day share price return of 2.40% offers a small bounce against a still weak 90 day share price return of 14.83%. At the same time, the 1 year total shareholder return of 25.92% hints that longer term momentum is not entirely broken. If...

Bausch Health Companies (NYSE:BHC) just reported strong early participation in its exchange offer, with investors tendering roughly 2.7 billion dollars of existing 2028 secured notes into new 10.0% notes due 2032. See our latest analysis for Bausch Health Companies. This heavy early take up comes as the 1 month share price return of 13.72 percent has started to claw back some of this year’s weakness. The 1 year total shareholder return remains negative, but the 3 year total shareholder return...

Nuvalent (NUVL) just saw a fresh jolt of attention after veteran oncology executive Ron Squarer joined its board, a move that arrived as Wall Street sentiment toward the cancer focused biotech has turned more confident. See our latest analysis for Nuvalent. That backdrop of growing confidence is showing up in the numbers, with Nuvalent’s share price at $103.8 after a strong 90 day share price return of 35.39 percent and an impressive three year total shareholder return of 264.98 percent. This...

Earlier this month, UiPath highlighted that it is generating free cash flow, has completed an US$819.64 million buyback of 67,772,000 shares, and is actively pursuing tuck-in acquisitions after buying Peak, while also integrating its automation platform with Talkdesk to streamline complex customer-service workflows such as healthcare prior authorizations. These moves underscore UiPath’s effort to pair disciplined capital deployment with deeper AI-driven partnerships, using its agentic...

Earlier this week, shares of crypto-exposed companies rallied after bitcoin moved past US$90,000, lifting sentiment across miners and trading platforms, including CleanSpark. The surge followed Hut 8’s 15-year, very large Fluidstack AI infrastructure deal and Coinbase’s push into tokenized assets and onchain AI tools, underscoring how AI-linked demand is reshaping investor interest in digital-asset infrastructure. We’ll now examine how bitcoin’s renewed momentum and AI-driven...

If you are wondering whether NVIDIA is still worth buying after its massive run, you are not alone. This breakdown is designed to give you a clear, no nonsense view of the stock's value. Despite a blockbuster long term performance, with the share price up 1091.4% over 3 years and 1296.8% over 5 years, more recent moves have been mixed, up 3.4% over the last week but down 3.0% over the last month, while still sitting on a 30.9% gain year to date and 34.4% over the past year. Recent headlines...

Revolution Medicines (RVMD) just hit an important clinical milestone, randomizing the first patient in its RASolute 304 Phase 3 trial of daraxonrasib for post-surgery pancreatic cancer patients after chemotherapy. See our latest analysis for Revolution Medicines. The news lands as the stock trades around $78.78, with a powerful 90 day share price return of 80.94 percent and a three year total shareholder return of 257.44 percent, signaling strong, building momentum around Revolution Medicines...

Chewy (CHWY) just cleared a modest hurdle with third quarter earnings that edged past expectations. The story behind that beat matters more than the headline numbers for anyone watching the stock. See our latest analysis for Chewy. The latest guidance tweak, calling for around 8% adjusted full year net sales growth, comes as Chewy’s share price has slid, with a 90 day share price return of minus 15.67% and a five year total shareholder return of minus 68.79%. This suggests long term holders...

Earlier this month, Match Group said that CEO Spencer Rascoff will join its Board of Directors and Hinge founder Justin McLeod, now leading Overtone, will become Chairman while continuing to advise Hinge through March 2026. The move brings a founder with deep dating-app product experience and a focus on responsible, human-centered technology into Match Group’s boardroom leadership. Next, we’ll explore how Justin McLeod’s appointment as Chairman may reshape Match Group’s investment narrative...

Allstate (ALL) has quietly outperformed many peers this year, but the stock has slipped slightly over the past month, giving long term investors a fresh chance to reassess its insurance driven earnings power. See our latest analysis for Allstate. That modest pullback comes after a solid year to date, with a 6.8% year to date share price return and a 1 year total shareholder return of 8.0% suggesting steady, if not explosive, momentum as investors reassess insurance sector risks and earnings...

International Business Machines (IBM) keeps edging higher, with the stock up roughly 4% over the past month and nearly 13% in the past 3 months, inviting a closer look at what might be driving sentiment. See our latest analysis for International Business Machines. That recent strength is not happening in isolation. The latest share price of $300.98 sits on top of a solid year to date share price return of roughly 37 percent and a powerful multi year total shareholder return north of 200...

Axon Enterprise recently secured multi-million dollar contracts for its AI-powered body cameras and drones, advanced plans to redeem its 0.50% convertible senior notes due 2027, and expanded its public-safety footprint through the acquisition of Prepared, an AI platform for 911 call centers. Together, these moves highlight how Axon is widening its role across public safety workflows while actively reshaping its balance sheet and long-term technology platform. Next, we’ll examine how Axon’s...

In the past week, Credicorp reported quarterly results that surpassed expectations, supported by strong loan growth, stable asset quality, and disciplined cost control across its banking, insurance, and wealth management operations. An interesting angle is Credicorp’s rapid digital ecosystem expansion, which is widening access to underpenetrated segments while reinforcing recurring, fee-based revenue streams amid Peru’s evolving financial system. We’ll now examine how Credicorp’s...

In recent weeks, J.B. Hunt Transport Services has drawn attention as investors reacted to past stronger-than-expected Q3 2025 results and upcoming Q4 earnings, alongside active options trading that highlights growing institutional interest. What stands out is how improving productivity and cost reductions are aligning with generally positive analyst views, even as day-to-day share performance has occasionally lagged sector peers. Next, we’ll examine how this combination of upbeat earnings...

Sally Beauty Holdings recently reported quarterly revenue up 1.3% year on year, beating analyst forecasts on revenue, EBITDA and EPS, while also issuing the largest full-year guidance increase among its peers. The company extended its ongoing share repurchase program to September 30, 2029, signaling management’s confidence in its earnings power and capital allocation priorities. We’ll now explore how this guidance upgrade and earnings beat may influence Sally Beauty’s existing investment...

Amentum Holdings (AMTM) is back on investors’ radar after landing two meaningful U.S. defense wins, including prime-contractor status on DTRA’s 3.5 billion CTRIC IV program and a separate 120 million DISA computing contract. See our latest analysis for Amentum Holdings. Those contract wins appear to be feeding into growing optimism, with the stock now at $29.21 and a strong year to date share price return alongside an even more impressive one year total shareholder return, signaling building...

In recent days, ZoomInfo Technologies has attracted renewed analyst attention as BTIG initiated coverage and KeyBanc issued an upgrade, both emphasizing the company’s AI product cycle, upmarket traction, and a record near–eight-figure annual contract win. This shift in analyst sentiment highlights how ZoomInfo’s AI-led offerings and larger enterprise deals are increasingly central to its go-to-market intelligence positioning. Now we’ll explore how this AI-driven analyst optimism,...

Byline Bancorp (BY) just rolled out a fresh share repurchase program, with board approval to buy back up to 2.25 million shares, roughly 5% of the float, running through the end of 2026. See our latest analysis for Byline Bancorp. The buyback comes after a strong run, with a 14.1% 1 month share price return and a 5 year total shareholder return of 113.1%, suggesting momentum is still quietly building around a $30.51 share price. If this capital return story has your attention, it could be a...

Terreno Realty Corporation recently announced that it has executed a lease for 117,000 square feet in Doral, Florida with an international freight forwarder, alongside early renewals for large industrial spaces in Washington, D.C. and Woodinville, Washington, all commencing between 2025 and 2026. Together, these agreements highlight Terreno Realty’s success in locking in long-term occupancy across key coastal markets with tenants ranging from a federal law enforcement agency to logistics and...

Earlier this month, Insmed announced that its Phase 2b BiRCh trial of brensocatib in chronic rhinosinusitis without nasal polyps failed to meet all primary and secondary efficacy endpoints, prompting an immediate halt to development in this indication despite a clean safety profile. At the same time, Insmed moved to bolster its respiratory and inflammatory pipeline by acquiring INS1148, a Phase 2–ready monoclonal antibody initially aimed at interstitial lung disease and moderate-to-severe...

If you have ever looked at Generac Holdings and wondered whether the current share price really reflects its long term potential, you are not alone. This article is designed to unpack exactly that question. After a choppy run, the stock is down 13.6% over the last week and 11.1% over the past year, but still sits about 50.7% higher than three years ago. This hints at a story that is more complicated than a simple up or down trend. Recently, investors have been weighing Generac's positioning...

Albertsons Companies (ACI) is under fresh scrutiny after the FDA cited the grocer for leaving recalled ByHeart infant formula linked to a botulism outbreak on shelves, raising clear questions about recall controls and compliance. See our latest analysis for Albertsons Companies. The FDA letter lands at a tricky time for Albertsons, with a 1 year to date share price return of negative 11.34 percent and a 1 year total shareholder return of negative 8.03 percent, signaling fading near term...